慢性肾病合并矿物质与骨代谢紊乱的发病机制、临床诊断与治疗

摘要/Abstract

摘要： 慢性肾病(CKD)患者的血液钙、磷、甲状旁腺激素、维生素D、成纤维细胞生长因子-23等生化因子的水平会发生异常, 这不仅能导致长期的系统性并发症, 还会引起骨矿物质代谢失衡, 造成骨损伤, 增加慢性肾病合并矿物质与骨代谢紊乱(CKD-MBD)的患病率和死亡率。本文对CKD-MBD的发病机制、临床诊断与治疗策略作一综述。

关键词: 慢性肾病, 骨代谢, 矿物质, 继发性甲状旁腺机能亢进, 维生素D

Abstract: The abnormal levels of calcium, phosphorus, parathyroid hormone, vitamin D, fibroblast growth factor-23 in the blood of patients with chronic kidney disease (CKD) will not only cause long-term systematic complications, but also lead to bone mineral metabolism imbalance and bone injury, and finally increase the risk of morbidity and mortality with CKD-MBD. In this review, we summarize the pathogenesis, clinical diagnosis and treatment strategy for CKD-MBD.

Key words: chronic kidney disease, bone metabolism, mineral, secondary hyperparathyroidism, vitamin D

中图分类号:

R692

潘海, 刘金鑫, 张岩. 慢性肾病合并矿物质与骨代谢紊乱的发病机制、临床诊断与治疗[J]. 中国临床药理学与治疗学, 2014, 19(6): 695-700.

PAN Hai, LIU Jin-xin, ZHANG Yan. Pathogenesis, clinical diagnosis and treatment for CKD-MBD[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 695-700.

参考文献

[1] Mejia N, Roman-Garcia P, Miar AB, et al. Chronic kidney disease-mineral and bone disorder: a complex scenario[J]. Nefrologia, 2011, 31(5): 514-519.
[2] Anca G, Stuart MS. Role of vitamin D deficiency in chronic kidney disease[J]. J Bone Miner Res, 2007, 22(S2): S91-94.
[3] Nickolas TL, Stein E, Cohen A, et al. Bone mass and microarchitecture in CKD patients with fracture[J]. J Am Soc Nephrol, 2010, 21(8): 1371-1380.
[4] Tomasello S. Secondary hyperparathyroidism and chronic kidney disease[J]. Diabetes Spectrum, 2008, 21(1): 19-25.
[5] Schumock GT, Andress DL, Marx SE, et al. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients[J]. Nephron Clin Pract, 2009, 113(1): 54-61.
[6] Kiattisunthorn K, Moe SM. Chronic kidney disease-mineral bone disorder (CKD-MBD)[J]. IBMS BoneKEy, 2010, 7(12): 447-457.
[7] Riggs MM, Peterson MC, Gastonguay MR. Multiscale physiology-based modeling of mineral bone disorder in patients with impaired kidney function[J]. J Clin Pharmacol, 2012, 52(1):45-53.
[8] Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications[J]. Endocr Rev, 2001, 22(4): 477-501.
[9] Kuro-O M. Phosphate and klotho[J]. Kidney Int Suppl , 2011, 79(121): S20-23.
[10]Anna J, Petra B, Michel C, et al. Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study[J]. J Clin Endocrin Metab, 2013, 98(8):3323-3331.
[11]Rodriguez M, Lopez I, Munoz J, et al. FGF-23 and mineral metabolism, implications in CKD-MBD[J]. Nefrologia, 2012, 32(3): 275-278.
[12]Moe SM, Chen NX, Seifert MF, et al. A rat model of chronic kidney disease-mineral bone disorder (CKD-MBD) and the effect of dietary protein source[J]. Kidney Int, 2009, 75(2): 176-184.
[13]Covic A, Kanbay M, Voroneanu L, et al. Vascular calcification in chronic kidney disease[J]. Clin Sci, 2010, 119(3): 111-121.
[14]Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta[J]. Arterioscler Thromb Vasc Biol, 2006, 26(7): 1423-1430.
[15]Proudfoot D, Shanahan CM. Molecular mechanisms mediating vascular calcification: role of matrix gla protein[J]. Nephrology, 2006, 11(5): 455-461.
[16]Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo[J]. J Exp Med, 2002, 196(8): 1047-1055.
[17]Shanahan CM, Proudfoot D, Farzaneh-Far A, et al. The role of gla proteins in vascular calcification[J]. Crit Rev Eukaryot Gene Expr, 1998, 8(3/4): 357-375.
[18]Kidney disease: improving global outcomes (KDIGO) CKD-MBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic disease-mineral and bone disorder (CKD-MBD) [J]. Kidney Int Suppl, 2009, (113):S1-130.
[19]Morrone LF, Russo D, Di Iorio B. Diagnostic workup for disorders of bone and mineral metabolism in patients with chronic kidney disease in the era of KDIGO guidelines[J]. Int J Nephrol, 2011, 2011:958798.
[20]Gao P, D'Amour P. Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation[J]. Clin Lab, 2005, 51(1/2): 21-29.
[21]Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease[J]. J Am Soc Nephrol, 2011, 22(1): 124-136.
[22]Jiang JQ, Lin S, Xu PC, et al. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder[J]. Nephrology, 2011, 16(6): 588-594.
[23]Ford ML, Smith ER, Tomlinson LA, et al. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart[J]. Nephrol Dial Transplant, 2012, 27(2): 727-733.
[24]Bacchetta J, Boutroy S, Juillard L, et al. Bone imaging and chronic kidney disease: will high-resolution peripheral tomography improve bone evaluation and therapeutic management[J]? J Ren Nutr, 2009, 19(1): 44-49.
[25]Bacchetta J, Boutroy S, Vilayphiou N, et al. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease[J]. J Bone Miner Res, 2010, 25(4): 849-857.
[26]Basu S, Hoilund-Carlsen PF, Alavi A. Assessing global cardiovascular molecular calcification with 18F-fluoride PET/CT: will this become a clinical reality and challenge to CT calcification scoring[J]? Eur Nucl Med Mol Imaging, 2012, 39(1): 660-664.
[27]Martin KJ, Gonzalez EA. Long-term management of CKD-mineral and bone disorder[J]. Am J Kidney Dis, 2012, 60(2): 308-315.
[28]Martin KJ, Gonzalez EA. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat[J]？ Clin J Am Soc Nephrol, 2011, 6(2): 440-446.
[29]Negi S, Shigematsu T. CKD-MBD (chronic kidney disease-mineral and bone disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease[J]. Clin Calcium, 2010, 20(7): 1096-1102.
[30]Cozzolino M, Mazzaferro S, Brandenburg V. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders[J]? Nephrol Dial Transplant, 2011, 26(2): 402-407.
[31]Kazama JJ. Oral phosphatebinders: history and prospects[J]. Bone, 2009, 45(S1) S8-12.
[32]Spaia S. Phosphate binders: sevelamer in the prevention and treatment of hyper- phosphataemia in chronic renal failure[J]. Hippokratia, 2011, 15(1): 22-26.
[33]Frazao JM, Adragao T. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects[J]. Nephron Clin Pract, 2012, 120(2): 108-119.
[34]Ogata H, Koiwa F, Kinugasa E, et al. CKD-MBD: impact on management of kidney disease[J]. Clin Exp Nephrol, 2007, 11(4): 261-268.
[35]Barreto FC, de Oliveira RA, Oliveira RB, et al. Pharmacotherapy of chronic kidney disease and mineral bone disorder[J]. Expert Opin Pharmacother, 2011, 12(17): 2627-2640.
[36]Martin KJ, Bell G, Pickthorn K, et al. Velcalcetide(AMG416), a novel peptide agonist of the calcium sensing receptor, reduce serum parathyroid hormone and FGF23 levels in healthy male subjects[J]. Nephrol Dial Transplant, 2014 , 29(2):385-392.
[37]Bover J, Aguilar A, Baas J, et al. Calcimimetics in the chronic kidney disease-mineral and bone disorder[J]. Int J Artif Organs, 2009, 32(2): 108-121.
[38]Bacchetta J, Harambat J, Cochat P, et al. The consequences of chronic kidney disease on bone metabolism and growth in children[J]. Nephrol Dial Transplant, 2012, 27(8): 3063-3071.
[39]Mitu G, Hirschberg R. Bone morphogenetic protein-7 (BMP7) in chronic kidney disease[J]. Front Biosci, 2008, 13(5): 4726-4739.
[40]Ott SM. Therapy for patients with CKD and low bone mineral density[J]. Nat Rev Nephrol, 2013, 9(11): 681-692.
[41]Berner A, Boerckel JO, Saifzadeh S, et al. Biomimetic tubular nanofiber mesh and platelet rich plasma-mediated delivery of BMP-7 for large bone defect regeneration[J]. Cell Tissue Res, 2012, 347(3): 603-612.
[42]Jha V, Kher V, Pisharody R, et al. Indian commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorders[J]. Indian J Nephrol, 2011, 21(3): 143-151.
[43]Tominaga Y, Matsuoka S, Sato T. Surgical indications and procedures of parathyroidectomy in patients with chronic kidney disease[J]. Ther Apher Dial, 2005, 9(1): 44-47.
[44]Onoda N, Kashiwagi T, Nakamura T, et al. Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients[J]. Ther Apher Dial, 2005, 9 (S1): S11-S15.
[45]Jofre R, Lopez Gomez JM, Menarguez J, et al. Parathyroidectomy: whom and when[J]? Kidney Int Suppl, 2003, 63 (85): S97-S100.
[46]Naranda J, Ekart R, Pecovnik-Balon B. Total parathyroidectomy with forearm autotransplantation as the treatment of choice for secondary hyperparathyroidism[J]. J Int Med Res, 2011, 39(3): 978-987.
[47]Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic points[J]. Clin J Am Soc Nephrol, 2011, 6(4): 913-921.